KVUE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KV

Mkt Cap

$36.31B

Volume

11.53M

Next Earnings

November 2nd

Loading chart

KV

KVUEKenvue Inc.

KVUE

Pay with—

Available Balance0.00

KV

Mkt Cap

$36.32B

Volume

11.53M

Next Earnings

November 2nd

Chart Financials Earnings News About Dividends Insider Filings

2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King)Johnson & Johnson and Realty Income are recommended as long-term dividend stocks. J&J, a Dividend King with 64 consecutive years of dividend increases, offers defensive healthcare stability through its innovative medicine and medtech businesses. Realty Income, with 136 monthly dividend increases, provides predictable income through its diversified commercial real estate portfolio with strong occupancy and expansion into data centers and private capital partnerships.The Motley Fool · Oct 10, 2026

NWL or KVUE: Which Is the Better Value Stock Right Now?In a comparison of two Consumer Products - Staples sector stocks, Newell Brands (NWL) emerges as the superior value investment option compared to Kenvue (KVUE). NWL holds a Zacks Rank #1 (Strong Buy) with a forward P/E of 7.21 and Value grade of A, while KVUE has a Zacks Rank #4 (Sell) with a forward P/E of 15.22 and Value grade of C. NWL's improving earnings outlook and stronger valuation metrics make it the more attractive choice for value investors.Zacks Investment Research · Oct 6, 2026

Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right NowKenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol and Neutrogena. However, uncertainty exists due to a pending acquisition by Kimberly-Clark (KMB), another Dividend King with a 5.23% yield.The Motley Fool · Sep 14, 2026

Kimberly Clark is Down 20% From Its 52-Week High. Is the Dip Worth Buying?Kimberly Clark, a Dividend King with an attractive 5% yield, has fallen 20% from its 52-week high. However, the company faces significant headwinds including lowered full-year guidance, a major acquisition of Kenvue that will increase leverage, high dividend payout ratio of 85%, and underperformance compared to better-run competitors like Procter & Gamble. Only aggressive dividend investors should consider buying at current levels.The Motley Fool · Sep 11, 2026

Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still AheadKenvue has secured shareholder approval and U.S. antitrust clearance for its planned Q4 2026 combination with Kimberly-Clark. However, the deal faces ongoing risks including weak Self Care segment performance, $8.5B debt burden, margin pressures from inflation and tariffs, restructuring costs, and pending litigation. Q2 results showed 3% sales growth but EPS missed estimates with adjusted gross margin declining 70 basis points.Zacks Investment Research · Sep 7, 2026

Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?Kenvue Inc. (KVUE) demonstrated improved profitability in the first half of 2026, with adjusted operating margins rising 180 basis points to 23.1% and earnings climbing 18.9%, driven primarily by cost-cutting initiatives. However, organic sales growth remained modest at 1.2%, with the Self Care segment struggling while Skin Health and Beauty showed stronger performance. The company faces headwinds from tariffs, inflation, and $8.5 billion in debt, with a pending merger with Kimberly-Clark expected to close in Q4 2026.Zacks Investment Research · Sep 7, 2026

Global Skin Care Products Market is Expected to Surpass the USD 260 Billion Mark by 2034 | DelveInsightThe global skin care products market is projected to grow from USD 166 billion in 2025 to USD 262 billion by 2034, with a CAGR of approximately 5%. Growth is driven by rising consumer awareness of skin health, increasing disposable incomes, demand for premium and personalized products, and the influence of social media trends. Asia-Pacific leads with 38% market share, while North America is the fastest-growing region. Key players include L'Oréal, Unilever, Procter & Gamble, and Estée Lauder.GlobeNewswire Inc. · Sep 2, 2026

This Consumer Staples Giant's Dividend Streak Rivals PepsiCo. Nobody Talks About It.Kimberly-Clark is an overlooked Dividend King with a 54-year consecutive dividend increase streak matching PepsiCo's. Despite lower brand recognition, KMB offers a higher yield (4.7% vs 4.1%), more resilient demand for household products, and is acquiring Kenvue to enhance its global portfolio, making it an attractive option for income-focused investors.The Motley Fool · Aug 24, 2026

2 Dividend Stocks to Buy and Never SellJohnson & Johnson and AbbVie are recommended as long-term dividend stocks to hold indefinitely. Both are Dividend Kings with strong cash flows, reliable dividend payments, and solid historical returns. JNJ has increased dividends for 64 consecutive years with a 1.96% yield, while ABBV has 54 years of increases with a higher 2.6% yield and stronger recent performance.The Motley Fool · Aug 23, 2026

This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing ItJohnson & Johnson is transitioning from a slow-growth dividend stock into a growth machine, driven primarily by its oncology business. The company's cancer drugs, particularly Darzalex, are growing at high-teen rates, positioning J&J to achieve its goal of $50 billion in annual cancer drug sales by 2030. With the global cancer treatment market expected to grow at 11.3% annually through 2035, J&J is well-positioned to capture significant market share despite being primarily viewed as an income investment.The Motley Fool · Jul 24, 2026

to start trading

KV

KVUEKenvue Inc.

KVUE

Pay with—

Available Balance0.00

Your PositionYou don't own any KVUE yet.

Related Tickers

Earnings

Dividends

Last · Sep 21Quarterly

Amount$0.21

Yield5.54%

Annual$1.04